Generate Biomedicines, Inc.(GENB)
$13.49-0.29 (-2.10%)
GENB
Generate Biomedicines, Inc. financials statements
$13.49
At close:-0.29 (-2.10%)
Want to see GENB full AI Analyst Report?
Generate Biomedicines, Inc. (GENB) Ratios
153 Followers
Generate Biomedicines, Inc. Ratios
GENB's free cash flow for Q2 2026 was $-58.88M. For the 2026 fiscal year, GENB's free cash flow was decreased by $-933.00K and operating cash flow was $-57.94M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 |
|---|---|---|
| Liquidity Ratios | ||
| Current Ratio | 2.85 | 4.70 |
| Quick Ratio | 2.85 | 4.70 |
| Cash Ratio | 1.48 | 2.03 |
| Solvency Ratio | -0.20 | -0.17 |
| Operating Cash Flow Ratio | -2.44 | -1.36 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 |
| Net Current Asset Value | $ -719.01M | $ -545.86M |
| Leverage Ratios | ||
| Debt-to-Assets Ratio | 0.21 | 0.15 |
| Debt-to-Equity Ratio | -0.11 | -0.18 |
| Debt-to-Capital Ratio | -0.13 | -0.22 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 |
| Financial Leverage Ratio | -0.54 | -1.19 |
| Debt Service Coverage Ratio | -183.67 | -77.39 |
| Interest Coverage Ratio | -206.92 | -92.98 |
| Debt to Market Cap | 0.00 | 0.00 |
| Interest Debt Per Share | 1.39 | 0.62 |
| Net Debt to EBITDA | 0.25 | 0.61 |
| Profitability Margins | ||
| Gross Profit Margin | 100.00% | 100.00% |
| EBIT Margin | -695.03% | -875.18% |
| EBITDA Margin | -653.71% | -800.16% |
| Operating Profit Margin | -737.04% | -962.60% |
| Pretax Profit Margin | -698.59% | -885.54% |
| Net Profit Margin | -636.99% | -849.36% |
| Continuous Operations Profit Margin | -699.10% | -886.57% |
| Net Income Per EBT | 91.18% | 95.91% |
| EBT Per EBIT | 94.78% | 91.99% |
| Return on Assets (ROA) | -61.53% | -33.53% |
| Return on Equity (ROE) | 32.98% | 39.99% |
| Return on Capital Employed (ROCE) | -94.79% | -45.63% |
| Return on Invested Capital (ROIC) | -89.38% | -43.93% |
| Return on Tangible Assets | -61.53% | -33.53% |
| Earnings Yield | -32.06% | -10.78% |
| Efficiency Ratios | ||
| Receivables Turnover | 0.00 | 66.43 |
| Payables Turnover | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.36 | 0.20 |
| Asset Turnover | 0.10 | 0.04 |
| Working Capital Turnover Ratio | 0.13 | 0.00 |
| Cash Conversion Cycle | 0.00 | 5.49 |
| Days of Sales Outstanding | 0.00 | 5.49 |
| Days of Inventory Outstanding | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 5.49 |
| Cash Flow Ratios | ||
| Operating Cash Flow Per Share | -4.01 | -0.92 |
| Free Cash Flow Per Share | -4.08 | -0.95 |
| Dividend Paid and CapEx Coverage Ratio | -57.09 | -34.16 |
| Capital Expenditure Coverage Ratio | -57.09 | -34.16 |
| Operating Cash Flow Coverage Ratio | -2.93 | -1.53 |
| Operating Cash Flow to Sales Ratio | -6.29 | -5.76 |
| Free Cash Flow Yield | -32.22% | -7.52% |
| Valuation Ratios | ||
| Price-to-Earnings (P/E) Ratio | -2.54 | -7.53 |
| Price-to-Sales (P/S) Ratio | 19.87 | 78.80 |
| Price-to-Book (P/B) Ratio | -1.03 | -3.71 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -3.10 | -13.30 |
| Price-to-Operating Cash Flow Ratio | -3.16 | -13.69 |
| Price-to-Earnings Growth (PEG) Ratio | -0.01 | 0.00 |
| Enterprise Value Multiple | -2.78 | -9.24 |
| Enterprise Value | 580.50M | 1.51B |
| EV to EBITDA | -2.78 | -9.24 |
| EV to Sales | 18.20 | 73.95 |
| EV to Free Cash Flow | -2.84 | -12.48 |
| EV to Operating Cash Flow | -2.89 | -12.85 |
| Tangible Book Value Per Share | -12.44 | -3.41 |
| Shareholders’ Equity Per Share | -12.30 | -3.41 |
| Tax and Other Ratios | ||
| Effective Tax Rate | -0.00 | -0.00 |
| Revenue Per Share | 0.64 | 0.16 |
| Net Income Per Share | -4.06 | -1.36 |
| Tax Burden | 0.91 | 0.96 |
| Interest Burden | 1.01 | 1.01 |
| Research & Development to Revenue | 7.05 | 8.57 |
| SG&A to Revenue | 1.33 | 2.06 |
| Stock-Based Compensation to Revenue | 0.65 | 0.95 |
| Income Quality | 0.90 | 0.65 |
Currency in USD
